Mounjaro (Tirzepatide)
Tirzepatide
Mounjaro (tirzepatide) is an FDA-approved injectable medication developed by Eli Lilly, originally indicated for type 2 diabetes management. As a dual GIP and GLP-1 receptor agonist, Mounjaro helps regulate blood sugar while supporting significant weight loss. By improving insulin sensitivity, slowing digestion, and reducing appetite, it has become a leading option for individuals seeking better metabolic health. Clinical studies show that patients using Mounjaro experience notable improvements in A1C levels and sustained weight reduction. Administered once weekly via injection, Mounjaro is quickly gaining attention as a groundbreaking treatment for type 2 diabetes and obesity-related conditions.
- Manufacturer: Eli Lilly
- Primary Use: Type 2 Diabetes and Weight Loss
- Form: Injectable
Common Side Effects
The most common side effects of Mounjaro (Tirzepatide) may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue
- Decreased Appetite
- Stomach pain
This is not a complete list. Always consult with your healthcare provider about potential side effects.
Medical Disclaimer
The information provided for Mounjaro (Tirzepatide) is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Read our full disclaimer.
Pricing & Deals
Average Monthly Price:
$1,000 – $1,200 per month (without insurance)
Find Coupons & Savings